Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash & Equivalents (2024 - 2025)

Historic Cash & Equivalents for Pyxis Oncology (PYXS) over the last 2 years, with Q3 2025 value amounting to $8.9 million.

  • Pyxis Oncology's Cash & Equivalents fell 2602.02% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year decrease of 2602.02%. This contributed to the annual value of $19.5 million for FY2024, which is N/A changed from last year.
  • Pyxis Oncology's Cash & Equivalents amounted to $8.9 million in Q3 2025, which was down 2602.02% from $10.7 million recorded in Q2 2025.
  • Over the past 5 years, Pyxis Oncology's Cash & Equivalents peaked at $28.0 million during Q1 2024, and registered a low of $8.9 million during Q3 2025.